Key Points
- CEO Leon Moulder, Jr. purchased 57,000 shares at an average price of $17.96 for a total of $1,023,720, boosting his direct stake to 423,155 shares (a 15.57% increase) as disclosed in an SEC filing.
- Zenas BioPharma shares opened at $19.72 and were trading up about 8.7%, with a market cap near $1.06 billion and a 1-year range of $6.11 to $44.60 (50-/200-day averages of $30.01/$25.30).
- Analyst coverage is mixed but broadly positive with a consensus rating of “Moderate Buy” and an average target of $43.14 (six Buys, one Hold, one Sell), while the company recently missed quarterly EPS expectations (reported -$1.22 vs. -$0.87 estimate).
Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. acquired 57,000 shares of Zenas BioPharma stock in a transaction dated Monday, February 2nd. The shares were bought at an average cost of $17.96 per share, for a total transaction of $1,023,720.00. Following the completion of the purchase, the chief executive officer directly owned 423,155 shares of the company's stock, valued at approximately $7,599,863.80. The trade was a 15.57% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Zenas BioPharma Trading Up 8.7%
NASDAQ ZBIO opened at $19.72 on Wednesday. The firm has a market cap of $1.06 billion, a PE ratio of -2.79 and a beta of -1.50. Zenas BioPharma, Inc. has a 1-year low of $6.11 and a 1-year high of $44.60. The stock has a 50-day moving average of $30.01 and a 200-day moving average of $25.30. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.37.
Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.35).
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the stock. Wall Street Zen cut shares of Zenas BioPharma from a "hold" rating to a "sell" rating in a research report on Saturday, January 10th. Citigroup boosted their price target on Zenas BioPharma from $27.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, October 28th. HC Wainwright restated a "buy" rating on shares of Zenas BioPharma in a report on Tuesday, December 16th. Morgan Stanley lowered Zenas BioPharma from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $37.00 to $19.00 in a research report on Monday, January 5th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Zenas BioPharma has a consensus rating of "Moderate Buy" and an average target price of $43.14.
Get Our Latest Research Report on ZBIO
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in ZBIO. Quarry LP lifted its stake in shares of Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company's stock valued at $25,000 after purchasing an additional 291 shares during the period. CWM LLC raised its holdings in Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company's stock worth $79,000 after purchasing an additional 709 shares in the last quarter. Two Sigma Investments LP lifted its position in Zenas BioPharma by 3.9% during the third quarter. Two Sigma Investments LP now owns 20,382 shares of the company's stock valued at $452,000 after buying an additional 765 shares during the period. Bank of America Corp DE boosted its holdings in shares of Zenas BioPharma by 5.8% during the 3rd quarter. Bank of America Corp DE now owns 14,809 shares of the company's stock valued at $329,000 after buying an additional 818 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Zenas BioPharma in the 4th quarter worth about $38,000.
Zenas BioPharma Company Profile
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company's proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.
Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
